Entospletinib,Lanraplenib
Kronos Bio,gilead
[]
the kronos bio team is presenting at #eha2022 this weekend! we are sharing new preclinical data about our syk inhibitor compounds, including our lead investigational candidate, entospletinib, which is being studied in the phase 3 agility trial. read more: 
We are focused on creating a world where no life is cut short by cancer or other serious diseases. Guidelines: https://t.co/a47vGmrq72